Similarly, combined trametinib and α-OX-40 antibody treatment, significantly (two-way ANOVA; P < 0.01) enhanced therapeutic efficacy in terms of delayed tumor growth (Fig. 6b, d) and extended survival (log ranked (Mantel–Cox); P < 0.01) in both models, compared to single agent therapy (Fig. 6f, h). This evidence concerns the gene TNFRSF4 and neoplasm.